Trial · NCT01227434

A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma

NCT01227434, Phase 2, Terminated, University of California, San Francisco; results first posted 2015-06-12

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma. Trials, record NCT01227434. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01227434

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma
NCT number: NCT01227434
Status: Terminated
Phases: Phase 2
Enrollment: 23 participants, actual
Lead sponsor: University of California, San Francisco
Conditions: Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma
Interventions: PD 0332991 (pre-surgery), PD 0332991, Resection as clinical care
First posted: 2010-10-25
Last updated: 2015-07-17
Results first posted: 2015-06-12

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Progression Free Survival	up to 142 weeks	Efficacy of the small molecule CDK4/6 inhibitor PD 0332991 in patients with recurrent glioblastoma multiforme or gliosarcoma who are Rb positive was measured by progression free survival. A total of 30 patients was intended to be treated; up to 15 patients were to undergo a planned, intended surgical resection and receive drug for 7 days prior to surgery, followed by drug after recovery from surgery; and up to 15 patients were to receive drug without a planned surgical procedure.
Secondary	Number of Participants With Adverse Events as a Measure of Safety and Tolerability	1-2 years	The number of participants with protocol related toxicity described by CTCAE version 4.0

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Progression Free Survival	up to 142 weeks		weeks	MEAN
SECONDARY	Number of Participants With Adverse Events as a Measure of Safety and Tolerability	1-2 years		participants	NUMBER

Source ClinicalTrials.gov

Results by group4

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Progression Free Survival	Surgical Group	4	Full Range 3 to 6	weeks
Progression Free Survival	Non-surgical Group	14	Full Range 1 to 142	weeks
Number of Participants With Adverse Events as a Measure of Safety and Tolerability	Surgical Group	6		participants
Number of Participants With Adverse Events as a Measure of Safety and Tolerability	Non-surgical Group	16		participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Surgical Group	6
Overall Study	STARTED	Non-surgical Group	16
Overall Study	COMPLETED	Surgical Group	6
Overall Study	COMPLETED	Non-surgical Group	16
Overall Study	NOT COMPLETED	Surgical Group	0
Overall Study	NOT COMPLETED	Non-surgical Group	0

Source ClinicalTrials.gov

Adverse events226

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Atrial fibrillation	Cardiac disorders	Surgical Group	0	6
other	Atrial fibrillation	Cardiac disorders	Non-surgical Group	1	16
other	Sinus tachycardia	Cardiac disorders	Surgical Group	1	6
other	Sinus tachycardia	Cardiac disorders	Non-surgical Group	2	16
other	Tinnitus	Ear and labyrinth disorders	Surgical Group	1	6
other	Tinnitus	Ear and labyrinth disorders	Non-surgical Group	0	16
other	Cushingoid	Endocrine disorders	Surgical Group	0	6
other	Cushingoid	Endocrine disorders	Non-surgical Group	1	16
other	Blurred vision	Eye disorders	Surgical Group	1	6
other	Blurred vision	Eye disorders	Non-surgical Group	0	16

1 to 10 of 226Source ClinicalTrials.gov

See all 226 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Surgical Group
Total, all-cause mortality	Non-surgical Group
Total, other adverse events	Surgical Group	4	6
Total, other adverse events	Non-surgical Group	15	16
Total, serious adverse events	Surgical Group	5	6
Total, serious adverse events	Non-surgical Group	4	16

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
30151703	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons2

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
Surgical Group vs Non-surgical Group: Number of Participants With Adverse Events as a Measure of Safety and Tolerability	Trial comparisons
Surgical Group vs Non-surgical Group: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT01227434

GET https://conductscience.org/api/trials/v1/NCT01227434/events?page=2

API reference For AI assistants